Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A Multi-epitope Vaccine Candidate Against Bolivian Hemorrhagic fever Caused by Machupo Virus

Z. Ali, JV. Cardoza, S. Basak, U. Narsaria, S. Bhattacharjee, UM. G, SP. Isaac, TCC. Franca, SR. LaPlante, SS. George

. 2024 ; 196 (4) : 2137-2160. [pub] 20230722

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24014513
E-resources Online Full text

NLK ProQuest Central from 1997-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2011-01-01 to 1 year ago
Health & Medicine (ProQuest) from 1997-01-01 to 1 year ago

Links

PubMed 37479961
DOI 10.1007/s12010-023-04604-9
Knihovny.cz E-resources

Bolivian hemorrhagic fever (BHF) caused by Machupo virus (MACV) is a New World arenavirus having a reported mortality rate of 25-35%. The BHF starts with fever, followed by headache, and nausea which rapidly progresses to severe hemorrhagic phase within 7 days of disease onset. One of the key promoters for MACV viral entry into the cell followed by viral propagation is performed by the viral glycoprotein (GPC). GPC is post-transcriptionally cleaved into GP1, GP2 and a signal peptide. These proteins all take part in the viral infection in host body. Therefore, GPC protein is an ideal target for developing therapeutics against MACV infection. In this study, GPC protein was considered to design a multi-epitope, multivalent vaccine containing antigenic and immunogenic CTL and HTL epitopes. Different structural validations and physicochemical properties were analysed to validate the vaccine. Docking and molecular dynamics simulations were conducted to understand the interactions of the vaccine with various immune receptors. Finally, the vaccine was codon optimised in silico and along with which immune simulation studies was performed in order to evaluate the vaccine's effectiveness in triggering an efficacious immune response against MACV.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014513
003      
CZ-PrNML
005      
20240905134113.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12010-023-04604-9 $2 doi
035    __
$a (PubMed)37479961
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ali, Zeeshan $u Krupanidhi College of Physiotherapy, Bangalore, Karnataka, 560035, India
245    12
$a A Multi-epitope Vaccine Candidate Against Bolivian Hemorrhagic fever Caused by Machupo Virus / $c Z. Ali, JV. Cardoza, S. Basak, U. Narsaria, S. Bhattacharjee, UM. G, SP. Isaac, TCC. Franca, SR. LaPlante, SS. George
520    9_
$a Bolivian hemorrhagic fever (BHF) caused by Machupo virus (MACV) is a New World arenavirus having a reported mortality rate of 25-35%. The BHF starts with fever, followed by headache, and nausea which rapidly progresses to severe hemorrhagic phase within 7 days of disease onset. One of the key promoters for MACV viral entry into the cell followed by viral propagation is performed by the viral glycoprotein (GPC). GPC is post-transcriptionally cleaved into GP1, GP2 and a signal peptide. These proteins all take part in the viral infection in host body. Therefore, GPC protein is an ideal target for developing therapeutics against MACV infection. In this study, GPC protein was considered to design a multi-epitope, multivalent vaccine containing antigenic and immunogenic CTL and HTL epitopes. Different structural validations and physicochemical properties were analysed to validate the vaccine. Docking and molecular dynamics simulations were conducted to understand the interactions of the vaccine with various immune receptors. Finally, the vaccine was codon optimised in silico and along with which immune simulation studies was performed in order to evaluate the vaccine's effectiveness in triggering an efficacious immune response against MACV.
650    12
$a virové vakcíny $x imunologie $7 D014765
650    _2
$a lidé $7 D006801
650    12
$a americká hemoragická horečka $x imunologie $x prevence a kontrola $7 D006478
650    _2
$a arenaviry Nového světa $x imunologie $7 D006477
650    _2
$a epitopy $x imunologie $x chemie $7 D000939
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a simulace molekulární dynamiky $7 D056004
655    _2
$a časopisecké články $7 D016428
700    1_
$a Cardoza, Jyothsna Volisha $u Krupanidhi College of Physiotherapy, Bangalore, Karnataka, 560035, India
700    1_
$a Basak, Srijita $u REVA University, Bangalore, India
700    1_
$a Narsaria, Utkarsh $u REVA University, Bangalore, India
700    1_
$a Bhattacharjee, Surjit $u Independent Researcher, Bangalore, India
700    1_
$a G, Unnati Meher $u Independent Researcher, Bangalore, India
700    1_
$a Isaac, Samuel Paul $u Krupanidhi College of Physiotherapy, Bangalore, Karnataka, 560035, India
700    1_
$a Franca, Tanos C C $u Military Institute of Engineering, Rio de Janerio, Brazil $u INRS - Centre Armand-Frappier Santé Biotechnologie, Université de Québec, Laval, Québec, H7V 1B7, Canada $u University of Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a LaPlante, Steven R $u INRS - Centre Armand-Frappier Santé Biotechnologie, Université de Québec, Laval, Québec, H7V 1B7, Canada
700    1_
$a George, Sudhan S $u Krupanidhi College of Physiotherapy, Bangalore, Karnataka, 560035, India. sudhan@krupanidhi.edu.in $1 https://orcid.org/000000034008482X
773    0_
$w MED00172606 $t Applied biochemistry and biotechnology $x 1559-0291 $g Roč. 196, č. 4 (2024), s. 2137-2160
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37479961 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134107 $b ABA008
999    __
$a ok $b bmc $g 2143958 $s 1226379
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 196 $c 4 $d 2137-2160 $e 20230722 $i 1559-0291 $m Applied biochemistry and biotechnology $n Appl Biochem Biotechnol $x MED00172606
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options